title: Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.
authors.affiliation: Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA. m-gheorghiade@northwestern.edu
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Gattis
authors.forename: Alejandro
authors.initials: A
authors.lastname: Barbagelata
authors.forename: Kirkwood F
authors.initials: KF
authors.lastname: Adams
authors.forename: Uri
authors.initials: U
authors.lastname: Elkayam
authors.forename: Cesare
authors.initials: C
authors.lastname: Orlandi
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000097:blood / Q000502:physiology*; D001552:Benzazepines / Q000627:therapeutic use; D018450:Disease Progression; D004311:Double-Blind Method; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006760:Hospitalization; D006801:Humans; D018579:Patient Selection; D011446:Prospective Studies; D017483:Receptors, Vasopressin / Q000502:physiology; D012107:Research Design; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D000077602:Tolvaptan